Results 21 to 30 of about 626,377 (227)

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review

, 2023
Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor.
Paweł Głuszak, Ewelina Jakielska, Wiesław Bryl, Marta Walczak   +3 more
core   +1 more source

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

The wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective

Journal of Education, Health and Sport, 2023
Introduction and aim. Cardiovascular diseases are the main cause of mortality in the world. One of the alterable risk factors of ischaemic heart disease is dyslipidemia.
Natalia Ilnicka, Patrycja Zuziak, Maria Sadlik, Daria Matyja, Leila Abod   +4 more
doaj   +1 more source

Small molecules as inhibitors of PCSK9: current status and future challenges [PDF]

, 2019
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulating lipoprotein metabolism by binding to low-density lipoprotein receptors (LDLRs), leading to their degradation.
Zhu, Zheying, Shanshan Luo, Jinyi Xu, Luo, Shanshan, Shengtao Xu, Zheying Zhu, Xu, Shengtao, Xu, Jinyi   +7 more
core   +1 more source

Inhibitors of PCSK9

Revue medicale suisse, 2017
Observational data show a consistent association between elevated low density lipoproteins (LDL-C) and cardiovascular disease (CVD). Reduction of LDL-C reduces the risk of CVD as has been shown by many trials. Statins are currently the most effective drugs for lowering LDL-C, but can present side effects which might limit the prescribed dosage and ...
Petrova-Slater, Iveta, Denegri, Andrea, Pasotti, Elena, Rossi, Maria Grazia, Spirk, David, Riesen, Walter F, Moccetti, Tiziano, Moccetti, Marco   +7 more
openaire   +3 more sources

A Comprehensive Review of PCSK9 Inhibitors

Journal of Cardiovascular Pharmacology and Therapeutics, 2022
Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) levels for which statins have been successful in reducing serum LDL-C to healthy concentrations.
Caroline Coppinger, Mohammad Reza Movahed, Veronica Azemawah, Lee Peyton, James Gregory, Mehrnoosh Hashemzadeh   +5 more
openaire   +3 more sources

PCSK9 Inhibition: From Current Advances to Evolving Future

Cells, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor (LDL-R) by binding LDL-R, reducing low-density lipoprotein ...
Chunping Liu, Jing Chen, Huiqi Chen, Tong Zhang, Dongyue He, Qiyuan Luo, Jiaxin Chi, Zebin Hong, Yizhong Liao, Shihui Zhang, Qizhe Wu, Huan Cen, Guangzhong Chen, Jinxin Li, Lei Wang   +14 more
doaj   +1 more source

Inadequate Response to PCSK9 Inhibitors. [PDF]

JACC Case Rep
Suboptimal response to various proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapies has been reported in the literature; however, inadequate response to proprotein convertase subtilisin/kexin type 9 monoclonal antibodies and small interference RNA is rare to our knowledge.A 68-year-old woman with hypercholesterolemia (baseline low-
Bimal T, Ayyalu T, Safarova MS, Donahoe S, Davila C, Dayspring T, Shapiro M, Gianos E.   +7 more
europepmc   +3 more sources

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. [PDF]

, 2016
Statins are the cornerstone of the management of dyslipidaemias and prevention of cardiovascular disease. Although statins are, overall, safe and well tolerated, adverse events can occur and constitute an important barrier to maintaining long-term ...
Windecker, Stephan, Wilhelm, Matthias, Koskinas, Konstantinos   +2 more
core   +2 more sources

PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. [PDF]

, 2022
OBJECTIVE To compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking maximally tolerated statin therapy or who are statin intolerant.
Guyatt, Gordon, Delvaux, Nicolas, Bekkering, Geertruida E Trudy, Rodondi, Nicolas, Yedlapati, Siva H., Lone, Ahmad N, Li, Sheyu, Hao, Qiukui, Vandvik, Per Olav, Bekkering, Geertruida E. Trudy, Yedlapati, Siva H, Khan, Safi U., Riaz, Irbaz Bin, Khan, Safi U, Aertgeerts, Bert, Bin Riaz, Irbaz, Lone, Ahmad N.   +16 more
core   +2 more sources